Available Technologies


285 available technologies

PosiSeat™: Assured Seating of Threaded Surgical Components

Vanderbilt presents an intraoperative device for taking the guesswork out of whether or not a threaded component is securely affixed to bone. This device is an anchor driver that automatically releases upon proper seating of the anchor on the bone of interest.

MultiUse Multimodal Imaging Chelates

PK11195 is a high-affinity ligand of the peripheral benzodiazepine receptor (PBR). By linking lanthanide chelates to the PK11195 targeting moiety, Vanderbilt researchers have generated a range of PBR-targeted imaging probes capable of visualizing a number of disease states at cellular levels using a variety of imaging modalities (fl uorescence, PET and SPECT, MRI, electron microscopy).

Peptide and Protein Fragmentation by Lysine Residue Originated Reactions

A method of modifying protein samples that comprises combining the sample with a peroxycarbonate solution and inserting the sample into a mass spectrometer. The present invention also includes methods of N-terminus characterization.

Human Monoclonal Antibodies to Infectious Diseases

Using human B cell hybridoma creation, and antibody engineering technologies, Dr. James E Crowe Jr.'s laboratory has developed an array of antibodies from full length human antibodies to Fab fragments and diabodies. Many of these antibodies are ready for a cooperate partner who can further develop these antibodies into biologic herapeutics. The table below is a sample of the antibodies they are currently researching and have available. In addition to these areas of research, Dr. Crowe is actively seeking collaborative opportunities to identify new interesting targets for future antibody engineering projects.

Molecular Profiles for Subtyping Triple Negative Breast Cancer

Personalized medicine is at the forefront of medical news and specialized diagnostics that can align patients with the correct treatment are the key to this type of medicine. Jennifer Pietenpol and colleagues have performed extensive research and discovered that triple negative breast cancer (TNBC) is a heterogeneous disease with at least six subtypes. These subtypes have differing biological behaviors and sensitivities to known therapeutics. Diagnostic assays will help guide personalized and more effective therapy.

Multisubstrate Inhibitors of Histone Acetylation Increase the Cytotoxicity of Chemotherapeutic Agents

Inhibitors of histone acetylation may constitute a novel class of potent therapy sensitizers applicable to a broad range of conventional cancer treatments.

HEK-293 cell line overexpressing neuronal potassium chloride cotransporter

KCC2 is a neuronal-specific K-CI cotransporter which plays a major role in maintaining intracellular Cl- concentration in neurons below its electrochemical equilibrium potential, thus favoring robust GABA hyperpolarizing or inhibitory responses.

A Conditionally Lethal Helicobacter Pylori Strain

The invention provides the dapE gene of Helicobacter pylori and H. pylori dapE.sup.- mutants and to methods of using the mutants to express foreign genes and immunize against foreign agents. The dapE gene can consist of the nucleotide sequence defined in SEQ ID NO:3. Nucleic acids of the gidA gene and ORF 2 of H. pylori are provided. Examples of these nucleic acids can be found in SEQ ID NO:1 and SEQ ID NO:5, respectively. Having provided these nucleic acids, hybridizing nucleic acids in accord with the description of hybridizing nucleic acids of dapE are also provided.

Method to model elasticity parameters (i.e. elastography) of tissue as a complement to imaging

Elastography is the direct imaging of tissue elasticity parameters. The invention is a widely-applicable framework for determining elastic properties of tissue called Modality Independent Elastography (MIE). The technology is an adaptable framework which augments existing technologies (i.e. optical, magnetic resonance, computed tomographic, ultrasound) and creates image distributions of elastic parameters. It does not require any special sequences other than routine anatomical images.

FOXA1 as a Biomarker for Urinary Bladder Cancer

In 2009 over 70,000 American were diagnosed with urinary bladder cancer, and in that same year over 14,000 Americans died of bladder cancer. Low funding for bladder cancer helps explain the slow progress in both the identification of biomarkers and the development of new treatments for metastatic bladder cancer. Nonetheless, novel diagnostic biomarkers are needed to aid in the early identification of patients with bladder cancer, and also to determine which patients are likely to progress. Vanderbilt researchers have identified such a biomarker whose expression is reduced and lost during progression of bladder cancer.

OLINDA/EXM Radiation Dose Assessment Software Application (FDA Approved)

The OLINDA/EXM® personal computer code performs dose calculations and kinetic modeling for radiopharmaceuticals (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). OLINDA® calculates radiation doses to different organs of the body from systemically administered radiopharmaceuticals and performs regression analysis on user-supplied biokinetic data to support such calculations for nuclear medicine drugs. These calculations are used to perform risk/benefit evaluations of the use of such pharmaceuticals in diagnostic and therapeutic applications in nuclear medicine. The technology employs a number of standard body models for adults, children, pregnant women and others, that are widely accepted and used in the internal dose community. The calculations are useful to pharmaceutical industry developers, nuclear medicine professionals, educators, regulators, researchers and others who study the accepted radiation doses that should be delivered when radioactive drugs are given to patients or research subjects.

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter